Powered by 
Google Übersetzer
Google Übersetzer
Novus Acquisition & Development Corp, operating as Novus Cannabis MedPlan (OTC: NDEV), is a leading national carrier of supplemental health insurance plans and a pioneer in incorporating cannabis coverage for recreational and medicinal users. The company recently updated its 10K 2024 results, highlighting favorable financial performance and critical catalysts for sustainable growth in the cannabis sector.
Ensuring Operational Independence Amid Delays in Federal Cannabis Regulations
Novus operates in the non-touching cannabis sector, a critical but often underestimated part of the cannabis industry. Unlike plant-touching sectors, Novus' growth is not hindered by delays in cannabis rescheduling or banking reform.
A look ahead in 2025: Novus will focus on its Dental and Prescription Drug Plans, which provide tax deductions on premiums that include cannabis benefits at no cost. These supplemental premiums within these plans may be tax-deductible if they do not exceed 7.5% of the consumer's adjusted gross income, making insurance premiums free of cost to the consumer.
Financial Performance
Novus Acquisition & Development Corp. also reported significant financial achievements:
No Sales of Insider Shares: No insider shares have been sold for the past three years, demonstrating strong confidence in the company’s future.
Gross Revenue Increase: Gross revenue increased by 7.32% compared to December 31, 2023, and December 31, 2022.
Total Shareholder Equity Increase: Total shareholder equity increased by 5.3% as of December 31, 2024, compared to December 31, 2023.
Net Revenue (EBITDA) Increase: EBITDA increased by 13.47% compared to December 31, 2023, and 2022.
Cash and Cash Equivalents Increase: Cash and cash equivalents increased by 7.95% compared to the financial reporting periods ending December 31, 2024, and December 31, 2023.
No Convertible Notes: No convertible notes have been issued or are outstanding.
Debt Transparency: CEO Frank Labrozzi is owed $163,425. This debt instrument has no equity conversion provision, and Mr. Labrozzi has no plans to exercise the call provision.
Controlled Vendor Share Liquidity: All vendors who received treasury-issued stock are contractually obligated to sell their shares gradually, limited to 15% of the average daily trading volume over the past 30 days, ensuring controlled liquidity.
Launch Rx Platform Rollout: Novus is rolling out its prescription drug plan, which includes cannabis, potentially allowing premiums to be tax-deductible for medical and recreational users.
Prioritizing Growth Despite Federal Regulations
In conclusion, the cannabis industry is on the verge of significant transformation, with Novus leading the charge through innovative approaches that enhance access to wellness solutions. This strategy is designed to benefit consumers while also driving shareholder value.
Novus has launched an innovative, no-cost platform designed to support cannabis businesses and health initiatives. This platform effectively meets market needs and promotes growth within the sector. Furthermore, the introduction of tax-deductible premiums will enable cannabis users to benefit from significant discounts as the industry consolidates and prices rise. This development will positively influence market positioning and financial performance, ultimately enhancing long-term shareholder value.
About Novus
Further Research:
Financial Filings: Click Here
Quote: Click Here
Investor's Page: Click Here
Novus (NDEV) operates through its wholly-owned subsidiary, WCIG Insurance Services, Inc. The company provides health plans as a health insurance carrier in states with legal medical marijuana programs. Novus' business model is based on receiving insurance premiums and does not involve the cultivation, distribution, or sale of cannabis or cannabis-related products.
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.
Investor Contact Information
855-228-7355
Email: info@getnovusnow.com
